Temocapril is a novel ACE inhibitor marketed in Japan for the treatment of
hypertension. Temocapril is three times more potent than enalapril by oral
administration, and has a long duration of action. It is characterized by a rapid onset
of action resulting from a fast conversion of temocapril to the active metabolite
diacid. Unlike most ACE inhibitors which are excreted mainly through the kidneys,
temocapril is excreted predominantly through the biliary route indicating that
temocapril is especially useful for treating hypertensive patients with renal
dysfunction. The potential usefulness of temocapril in the treatment of congestive
heart failure has been reported.
Angiotensin-converting enzyme (ACE) inhibitor. Hydrolyzed in vivo to the active diacid metabolite.
angiotensin-converting enzyme inhibitor (ACE-I)
ChEBI: Temocapril hydrochloride is a dipeptide.
